J&J PhC leads Aquinox $18m C round
This article was originally published in Scrip
Aquinox Pharmaceuticals has raised US $18 million in a Series C venture capital financing, enabling it to conduct two more Phase II trials of its lead product, the anti-inflammatory AQX-1125. Aquinox has attracted the interest of phenture capitalists: both Pfizer’s and J&J’s corporate funds participated in earlier rounds and the Johnson & Johnson Development Corporation led this latest round. Intriguingly, given Europe’s latest financial meltdown, they are joined in the latest round by Augment Investments, the Cyprus-incorporated majority shareholder of Russian pharmaceutical company, OJSC Pharmstandard.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.